Hydrochloric Acid → Pioglitazone hydrochloride, (R)-

HRID 1522791

반응식

HRID 1522791 반응식
[ClH:1].[CH2:2]([C:4]1[CH:5]=[CH:6][C:7]([CH2:10][CH2:11][O:12][C:13]2[CH:26]=[CH:25][C:16]([CH2:17][C@H:18]3[S:22][C:21](=[O:23])[NH:20][C:19]3=[O:24])=[CH:15][CH:14]=2)=[N:8][CH:9]=1)[CH3:3]>CO>[ClH:1].[CH2:2]([C:4]1[CH:5]=[CH:6][C:7]([CH2:10][CH2:11][O:12][C:13]2[CH:26]=[CH:25][C:16]([CH2:17][C@H:18]3[S:22][C:21](=[O:23])[NH:20][C:19]3=[O:24])=[CH:15][CH:14]=2)=[N:8][CH:9]=1)[CH3:3]

참가 물질

4

반응물 2

HCID 313Hydrochloric AcidHCID 29010894Pioglitazone, (R)-

생성물 1

HCID 53358444Pioglitazone hydrochloride, (R)-수율 100%

시약·촉매·용매 1

HCID 887Methanol용매2회

실험 절차

˜1.25 M HCl in MeOH (0.33 mL, 0.33 mmol) was added to a suspension of (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione (from Example 1) (30 mg, 0.084 mmol) in MeOH (5 mL) and stirred at RT for 1 h. The solvent was removed in vacuo to afford the title compound (32.4 mg, 100%). LCMS (Method 4): Rt 5.95 min, m/z 357 [M-HCl+]. e.e (Method 3) 93.2%, Rt 12.10 min. Stereochemisty at C-5 was assigned (R) configuration by single crystal X-ray diffraction analysis. [α]D24+108° (c 1.0, MeOH). 1H NMR (400 MHz, DMSO-d6): δ 12.03-11.88 (1H, bs), 8.68-8.62 (1H, d, J 1.7), 8.34-8.25 (1H, d, J 7.9), 7.91-7.83 (1H, d, J 8.3), 7.14-7.05 (2H, d, J 8.7), 6.86-6.77 (2H, d, J 8.7), 4.85-4.77 (1H, dd, J 4.3, 8.9), 4.38-4.28 (2H, t, J 6.0), 3.42-3.36 (2H, t, J 6.2), 3.28-3.20 (1H, dd, J 9.0, 14.2), 3.06-2.96 (1H, dd, J 9.0, 14.2), 2.77-2.67 (2H, q, J 7.7), 1.23-1.15 (3H, t, J 7.7). Subsequent recrystallisations using MeOH-EtOAc or MeOH-Et2O gave the title compound with an e.e. >97%.

후처리

  1. customThe solvent was removed in vacuo

출처 및 근거

ORD 기록
ord-a9c9f9d6f57c4415a05fa50548c6f9bd
출처 데이터셋
uspto-grants-2015_07
특허 번호
US09078885B2

연결된 노트

불러오는 중…